Current Concepts on the Pathogenesis of Systemic Sclerosis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 3×
“Specificities related to organs and tissues undergoing fibrotic changes are being unraveled by “omics” studies at single-cell level and are revealing the presence of rare cell types with specific phenotypic and functional characteristics [91].”
BackgroundInfluentialFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940 · cited 1×
“Further, IL-13 may enhance the production of TGF-β by macrophages thus indirectly enhancing ECM deposition [153].”
BackgroundImmune-microbiota interactions in health and disease
Palm, N. W., de Zoete, M. R., & Flavell, R. A. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.014 · Cited by 315
Manetti, M., Romano, E., Rosa, I., Guiducci, S., Bellando-Randone, S., De Paulis, A., Ibba-Manneschi, L., & Matucci-Cerinic, M. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210229 · Cited by 278 · cited 1×
“Transdifferentiation of EC via the process of endothelial-mesenchymal transition (EndoMT) and more likely of pericytes into profibrotic myofibroblasts may contribute further to vascular wall fibrosis [77].”
BackgroundSkaug, B., Khanna, D., Swindell, W. R., Hinchcliff, M. E., Frech, T. M., Steen, V. D., Hant, F. N., Gordon, J. K., Shah, A. A., Zhu, L., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215894 · Cited by 179 · cited 2×
“T Cells in SSc Skin Compared to healthy skin, T cells are abundant in involved SSc more so early in disease course and active collagen synthesis is more pronounced around inflammatory infiltrates [150, 151].”
BackgroundFrançois, A., Chatelus, E., Wachsmann, D., Sibilia, J., Bahram, S., Alsaleh, G., & Gottenberg, J.-E. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4352 · Cited by 149
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., Utz, P. J., Genovese, M. C., Whitfield, M. L., & Chung, L. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0669-3 · Cited by 117
Stifano, G., Affandi, A. J., Mathes, A. L., Rice, L. M., Nakerakanti, S., Nazari, B., Lee, J., Christmann, R. B., & Lafyatis, R. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4598 · Cited by 86
Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
Cited by
Volkmann, E. R., Andréasson, K., & Smith, V. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 616
Inflammation and DNA damage: cause, effect or both
Pezone, A., Olivieri, F., Napoli, M. V., Procopio, A., Avvedimento, E. V., & Gabrielli, A. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00905-1 · Cited by 212
Swain, H. N., Boyce, P. D., Bromet, B. A., Barozinksy, K., Hance, L., Shields, D., Olbricht, G. R., & Semon, J. A. (2024) · Biochimie · doi:10.1016/j.biochi.2024.04.009 · Cited by 13
(2026) · doi:10.3389/fphar.2026.1769883 · Cited by 1
Metadata
- Authors
- Truchetet, M. E., Brembilla, N. C., & Chizzolini, C.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2021-09-06
- Volume
- 64
- Issue
- 3
- Pages
- 262-283
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W3196540627
- Cited by
- 170
- References
- 12
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.